BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 23490332)

  • 21. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome.
    Salani R; Santillan A; Zahurak ML; Giuntoli RL; Gardner GJ; Armstrong DK; Bristow RE
    Cancer; 2007 Feb; 109(4):685-91. PubMed ID: 17219441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.
    Zang RY; Zhang ZY; Li ZT; Chen J; Tang MQ; Liu Q; Cai SM
    J Surg Oncol; 2000 Sep; 75(1):24-30. PubMed ID: 11025458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
    Cascales-Campos PA; Gil J; Feliciangeli E; Gil E; González-Gil A; López V; Ruiz-Pardo J; Nieto A; Parrilla JJ; Parrilla P
    Ann Surg Oncol; 2015 Mar; 22(3):987-93. PubMed ID: 25212832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.
    Takei Y; Takahashi S; Machida S; Taneichi A; Yoshiba T; Takahashi Y; Yoshida C; Saga Y; Matsubara S; Fujiwara H
    Int J Clin Oncol; 2018 Oct; 23(5):930-935. PubMed ID: 29679177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
    Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
    Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group.
    Vincent L; Jankowski C; Ouldamer L; Ballester M; Bendifallah S; Bolze PA; Akladios C; Costaz H; Lavoué V; Canlorbe G; Collinet P; Touboul C; Huchon C; Bricou A; Dridi S; Padéano MM; Bengrine L; Arnould L; Coutant C;
    Eur J Surg Oncol; 2020 Sep; 46(9):1689-1696. PubMed ID: 32417154
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer.
    Gouy S; Goetgheluck J; Uzan C; Duclos J; Duvillard P; Morice P
    Eur J Surg Oncol; 2012 Feb; 38(2):170-5. PubMed ID: 22104389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
    Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
    Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nondysgerminomatous ovarian tumors: clinical characteristics, treatment, and outcome. A case-controlled study.
    Ghaemmaghami F; Hasanzadeh M; Karimi Zarchi M; Fallahi A
    Int J Surg; 2008 Oct; 6(5):382-6. PubMed ID: 18715834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: A population-based study.
    Zhou J; Zhang WW; Zhang QH; He ZY; Sun JY; Chen QH; Wu SG
    Int J Surg; 2018 Apr; 52():11-15. PubMed ID: 29432972
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of guideline adherence on patient outcomes in early-stage epithelial ovarian cancer.
    Lee JY; Kim TH; Suh DH; Kim JW; Kim HS; Chung HH; Park NH; Song YS; Kang SB
    Eur J Surg Oncol; 2015 Apr; 41(4):585-91. PubMed ID: 25624160
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of recurrent ovarian cancer.
    Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
    Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.